Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AANAmerican Academy of Neurology
AChRAcetylcholine receptor
AEAdverse event
AHFSAmerican Hospital Formulary Service
BCMAB-cell maturation antigen
BLABiologics license application
C5Complement component 5
CARChimeric antigen receptor
CAR-TChimeric antigen receptor T-cell (therapy)
CDCluster of differentiation
cGMPCurrent good manufacturing practice
CIConfidence interval
CMSCenters for Medicare & Medicaid Services
CRSCytokine release syndrome
DNADeoxyribonucleic acid
DRGDiagnosis-related group
EBMTEuropean Society for Blood and Marrow Transplantation
EQ-5D-5LEuroQol 5-dimension, 5-level questionnaire
evLYGEqual value of life-years gained
FcRnNeonatal Fc receptor
FDAU.S. Food and Drug Administration
FYFiscal year
G-CSFGranulocyte colony-stimulating factor
gMGGeneralized myasthenia gravis
HIVHuman immunodeficiency virus
HSVHerpes simplex virus
ICAHTImmune effector cell-associated hematotoxicity
ICANSImmune effector cell-associated neurotoxicity syndrome
ICERInstitute for Clinical and Economic Review
IgGImmunoglobulin G
IRRInfusion-related reaction
ITTIntention-to-treat
IVIntravenous
IVIgIntravenous immunoglobulin
JACIEJoint Accreditation Committee of ISCT and EBMT
JAKJanus kinase
JDMJuvenile dermatomyositis
LRP4Low-density lipoprotein receptor-related protein 4
MGMyasthenia gravis
MG-ADLMyasthenia Gravis Activities of Daily Living
MG-QoL-15rMyasthenia Gravis Quality of Life 15-item revised
MGCMyasthenia Gravis Composite
MGFAMyasthenia Gravis Foundation of America
MGTXThymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone
mITTModified intention-to-treat
mRNAMessenger ribonucleic acid
MS-DRGMedicare severity diagnosis-related group
mTORMechanistic target of rapamycin
MuSKMuscle-specific tyrosine kinase
NCINational Cancer Institute
NHSNational Health Service
pDCPlasmacytoid dendritic cell
PISPostintervention status
QALYQuality-adjusted life-year
QMGQuantitative Myasthenia Gravis
REMSRisk Evaluation and Mitigation Strategy
RNARibonucleic acid
SAESerious adverse event
SDStandard deviation
UKUnited Kingdom
USUnited States
USDU.S. dollars